PT 141

Summary

PT-141 is one of the reference peptides in the field of sexual function and neuroendocrinology: it is being researched for its role in sexual desire and response through the central nervous system. Technically, it is a cyclic 7-amino acid peptide, an analog of α-MSH, which acts as an agonist of melanocortin receptors (mainly MC4R and MC1R) and, unlike vascular modulators, exerts its action at the central level.

What is it researched for?

• •  Central-origin sexual desire and response
• •  Female and male sexual function
• •  Biology of the melanocortin system
• •  Hypothalamic MC4R receptor signaling

Cycle and rest

Mechanism of action

Melanocortin receptor agonism (MC4R/MC1R)

It activates melanocortin receptors in the central nervous system, especially hypothalamic MC4R, a pathway involved in regulating sexual desire independent of the vascular route.

Central, not vascular, pathway

Its mechanism differs from that of PDE5 inhibitors: instead of acting on blood flow, it modulates brain signals associated with arousal.

Research in sexual function

It is being researched in both female and male sexual dysfunction, as well as in the biology of the melanocortin system.

Scientific evidence

Central mechanism: PT-141 was approved by the FDA in 2019 (Vyleesi) for hypoactive sexual desire in premenopausal women, which supports its central mechanism of action.

Phase 3 trials: Phase 3 clinical trials (RECONNECT program) documented an increase in sexual desire compared to placebo.

Sexual function: Clinical programs have evaluated its effect on sexual response in both sexes.

Product use

Due to its central mechanism via the melanocortin system, PT-141 is a unique reference material for research into sexual function and neuroendocrinology. At Peptido BioGenetic, we supply it as a high-purity peptide for laboratory use, with a certificate of analysis (COA) available upon request.

⚠️ Product intended exclusively for research and laboratory use. Not suitable for human or veterinary consumption.